Mohamed elnaggar

Dr. Mohamed elnaggar

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Aml Imam Abd El Ghany AhmedAml Imam Abd El Ghany Ahmed
Aml Imam Abd El Ghany Ahmed
NENermin E. Eleraky
Nermin E. Eleraky
Ghareb M. SolimanGhareb M. Soliman
Ghareb M. Soliman
MEMohamed elnaggar
Mohamed elnaggar
MEMarwa G Elnaggar
Marwa G Elnaggar
Breast cancer is the most widespread cancer in women with rising incidence, prevalence, and mortality in developed regions. Most breast cancers (80%) are estrogen receptor–positive, indicating that disease progression could be controlled by estrogen inhibition in the breast tissue. However, drug resistance limits the benefits of this approach. Combinatorial treatment could overcome the resistance and improve the outcome of breast cancer treatment. In the current study, we prepared letrozole-(LTZSPs) and quercetin-loaded spanlastics (QuSPs) using different edge activators—Tween 80, Brij 35, and Cremophor RH40—with different concentrations. The spanlastics were evaluated for their average particles size, surface charge, and percent encapsulation efficiency. The optimized formulations were further examined using transmission electron microscopy, Fourier transform infrared spectroscopy, in vitro drug release and ex vivo skin permeation studies. The prepared spherical LTZSPs and QuSPs had average particle sizes ranged between 129–310 nm and 240–560 nm, respectively, with negative surface charge and high LTZ and Qu encapsulation (94.3–97.2% and 97.9–99.6%, respectively). The in vitro release study of LTZ and Qu from the selected formulations showed a sustained drug release for 24 h with reasonable flux and permeation through the rat skin. Further, we evaluated the in vitro cytotoxicity, cell cycle analysis, and intracellular reactive oxygen species (ROS) of the combination therapy of letrozole and quercetin either in soluble form or loaded in spanlastics against MCF-7 breast cancer cells. The LTZSPs and QuSPs combination was superior to the individual treatments and the soluble free drugs in terms of in vitro cytotoxicity, cell cycle analysis, and ROS studies. These results confirm the potential of LTZSPs and QuSPs combination for transdermal delivery of drugs for enhanced breast cancer management.

5 October 2022 in Molecular Cytogenetics
Verified
Journal Article
Open access
PDF file
MEMohamed elnaggar
Mohamed elnaggar
EMEman Mosad
Eman Mosad
AMAhmed Makboul
Ahmed Makboul
ESEngy Adel Shafik
Engy Adel Shafik
Background: Acute myeloid leukemia (AML) is a diverse disease characterized by the expansion of blasts of myeloid lineage. Cytogenetic testing is the cornerstone for risk stratification of AML patients. Geographical and environmental factors may play a very important role in the development of leukemia and several differences in genetic profile may be seen among different ethnicities. In our study, we evaluated cytogenetic findings of adult AML patients in South Egypt. Methods: Cytogenetic testing (karyotyping and M-FISH) was performed for 120 adult patients with AML. Twenty metaphases were analyzed for each patient. Results: In our study, the median age of AML patients was 36.5 years, with an age range between 18 and 86 years. 56.7% of patients had normal karyotypes and 43.3% of patients had clonal cytogenetic abnormalities. t (15;17) was the most detected structural abnormality, and + 8 was the most detected numerical abnormality. Regarding cytogenetic risk stratification, 65% of patients were in the intermediate-risk category. Conclusion: The cytogenetic profile of AML patients in our locality showed some differences and some similarities with cytogenetic profiles in different Arab, Asian and Western countries. Further studies are needed using advanced techniques such as next-generation sequencing and optical genome mapping to elucidate more ethnic and geographic genetic heterogeneity among different countries.

9 November 2023 in Microorganisms
Verified
Journal Article
Open access
PDF file
HAHajir Ali AlSaihati
Hajir Ali AlSaihati
HHHosni A. M. Hussein
Hosni A. M. Hussein
ATAli A Thabet
Ali A Thabet
AWAhmed A. Wardany
Ahmed A. Wardany
SMSabry Mahmoud
Sabry Mahmoud
AZAsmaa M. Zahran
Asmaa M. Zahran
The immune response implicated in Coronavirus disease 2019 (COVID-19) pathogenesis remains to be fully understood. The present study aimed to clarify the alterations in CD4+ and CD8+ memory T cells’ compartments in SARS-CoV-2-infected patients, with an emphasis on various comorbidities affecting COVID-19 patients. Peripheral blood samples were collected from 35 COVID-19 patients, 16 recovered individuals, and 25 healthy controls, and analyzed using flow cytometry. Significant alterations were detected in the percentage of CD8+ T cells and effector memory-expressing CD45RA CD8+ T cells (TEMRA) in COVID-19 patients compared to healthy controls. Interestingly, altered percentages of CD4+ T cells, CD8+ T cells, T effector (TEff), T naïve cells (TNs), T central memory (TCM), T effector memory (TEM), T stem cell memory (TSCM), and TEMRA T cells were significantly associated with the disease severity. Male patients had more CD8+ TSCMs and CD4+ TNs cells, while female patients had a significantly higher percentage of effector CD8+CD45RA+ T cells. Moreover, altered percentages of CD8+ TNs and memory CD8+CD45RO+ T cells were detected in diabetic and non-diabetic COVID-19 patients, respectively. In summary, this study identified alterations in memory T cells among COVID-19 patients, revealing a sex bias in the percentage of memory T cells. Moreover, COVID-19 severity and comorbidities have been linked to specific subsets of T memory cells which could be used as therapeutic, diagnostic, and protective targets for severe COVID-19.

26 June 2020 in Cureus
Verified
Journal Article
Open access
PDF file
MEMohamed elnaggar
Mohamed elnaggar
SMSumaiya Mahboob
Sumaiya Mahboob
BBBryce David Beutler
Bryce David Beutler
AHAhmed Hanfy
Ahmed Hanfy
OCOmar Canaday
Omar Canaday
Streptococcus mitis (S. mitis) is a commensal bacterial species that commonly colonizes the oropharynx and gastrointestinal tract. It is seldom reported as a human pathogen. However, immunocompromised individuals may be at risk of infection. We describe a 62-year-old male with prostate cancer who presented with multiple S. mitis abscesses masquerading as metastases. In addition, we discuss the differential diagnosis and treatment options for this rare opportunistic infection.

1 January 1998 in Journal of Urologic Pathology
Verified
Journal Article
Closed access
AMAnwar N. Mohamed
Anwar N. Mohamed
MEMohamed elnaggar
Mohamed elnaggar
FKFred C. Koppitch
Fred C. Koppitch
KBKhldoun M. Bakdounes
Khldoun M. Bakdounes
DGDavid J. Grignon
David J. Grignon

9 March 2022 in Research Square
Verified
Preprint
Open access
PDF file
HHHosny B. Hamed
Hosny B. Hamed
ENEman M. Naguib
Eman M. Naguib
MMMonica B. Mosaad
Monica B. Mosaad
MEMohamed elnaggar
Mohamed elnaggar
Background:The Ten-Eleven Translocation 1 gene (TET1) is a member of the TET methyl cytosine dioxygenase family of enzymes (TET1, TET2, and TET3). The TET1 has contrasting roles in myeloid and lymphoid transformation being either an oncogene or a tumor suppressor. This work aimed to study the expression level of TET1 gene in acute leukemia patients and its correlation with the clinical and pathological criteria of these patients. Patients & methods:This study was conducted on 73 acute leukemia patients. Bone marrow samples were analyzed using Real-Time PCR 7500s.Results:There was a significant correlation between expression levels of TET 1 gene in acute leukemia patients and their clinical and pathological criteria.Conclusion:It has been found that expression levels of TET1 gene in patients’ samples were higher in AML, not otherwise specified (NOS), and T lymphoblastic leukemia/lymphoma patients and lower in B lymphoblastic leukemia/lymphoma, NOS patients. Besides, this study showed the significant relation between TET1 gene and the percentage of blast cells in peripheral blood (P.B) and bone marrow (B.M) and generalized lymphadenopathy. These findings revealed the great role of TET1 gene dysregulation in leukemogenesis; also its possible usage as a potential target for treating this form of hematopoietic malignancy.